Category: Media Release

30 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from our preclinical cardioprotection program in collaboration with researchers from the University of Newcastle (ASX announcement: 28 April 2021). This program aimed at exploring the…

28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results from our preclinical melanoma research program in collaboration with the University of Newcastle (ASX announcement: 19 March 2021). This program aimed to explore the use…

Zantrene Improves Cancer Immunotherapy in a Mouse Model of Treatment Resistant Melanoma

22 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from its preclinical melanoma research program (ASX announcement: 19 March 2021). The program’s objective was to explore the use of Zantrene® (bisantrene dihydrochloride) in novel…

21 June 2022 – Race Oncology Limited (“Race”) is pleased to announce that two peer reviewed research poster abstracts detailing new preclinical data on the anti-cancer uses of Zantrene (also known as bisantrene or CS1) have been published in the…

09 June 2022 – Race Oncology Limited (“Race”) is pleased to announce the Board has approved an on-market share buyback for up to 4 million Race Oncology ordinary shares over the next 12 months. Race Oncology’s Board believes an on-market…

08 June 2022 – Race Oncology Limited (“Race”) is pleased to announce it is expanding the FTO-targeted BISECT (RAC-006) clinical trial in extramedullary Acute Myeloid Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS) to include five additional trial sites in Spain…

Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed using a 4-day treatment of Zantrene in combination with fludarabine and clofarabine Encouraging clinical responses were observed in this very heavily pre-treated AML patient population…

Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO) approval from the Calvary Mater Newcastle Hospital for its open label clinical trial of Zantrene® (bisantrene dihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML)…